Allos Therapeutics Announces Dismissal of Securities Class Action Lawsuit

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the only remaining securities class action lawsuit that had been brought against the company and one of its officers in May 2004 has been dismissed with prejudice. In an opinion dated October 20, 2005, the United States District Court for the District of Colorado concluded that the plaintiff's complaint failed to meet the legal pleading requirements applicable to its alleged claims. The plaintiff has 30
days to determine whether it will appeal the decision to the U.S. Court of Appeals for the Tenth Circuit.

"We are extremely pleased with the result," said Marc H. Graboyes, Vice President, General Counsel of Allos. "We have always believed that the plaintiff's case lacked merit, and we are gratified that the court agreed. We are excited to put this behind us and continue moving forward with our on-going clinical trials and product development efforts."

About Allos Therapeutics, Inc. Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company focused on developing and commercializing innovative small molecule therapeutics for the treatment of cancer. Allos' lead product candidate, EFAPROXYN, is a synthetic small molecule designed to sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation therapy. EFAPROXYN is currently being evaluated as an adjunct to whole brain radiation therapy in a pivotal Phase 3 trial in women with brain metastases originating from breast
cancer.

Allos' other product candidates are: PDX (pralatrexate), a small molecule chemotherapeutic agent (DHFR inhibitor) currently under investigation as both a single agent and in combination therapy regimens in patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1, a small molecule chemotherapeutic agent bioactivated by the enzyme DT-diaphorase currently under evaluation in patients with advanced solid tumors.

Related Articles

• Lawsuit Funding Helps Young Family Survive
  22 October 2005



• Glancy Binkow & Goldberg LLP, Representing Shareholders of World Health Alternatives, Inc., Announces Update to Shareholder Lawsuit -- WHAI
  22 October 2005



• Spector, Roseman & Kodroff, P.C. Announces the Filing of a Class Action Suit Against Dana Corporation -- DCN
  22 October 2005



• DHB Industries, Inc. Shareholders File Class Action Lawsuit
  21 October 2005



• Chicago Lawsuit Alleges Violations by Stone Park Police
  21 October 2005



• Lawsuit Against TASER(TM) International Dismissed
  21 October 2005



• Shareholder Class Action Filed on Behalf of Shareholders of Refco, Inc. by the Law Firm of Schiffrin & Barroway, LLP
  20 October 2005



• Nationwide Class Action Filed Against UBS Financial Services, Inc. Alleging a Company-wide Practice of Racial Discrimination
  19 October 2005



• Humana Settles Physicians' Class Action
  19 October 2005



• Chamber Calls on House to Help Stop Lawsuit Abuse; Much-Needed Tort Reform Legislation Scheduled for Floor Votes
  19 October 2005



• Notice of Filing Securities Class Action Against Immucor, Inc. and Certain of Its Former and Current Officers
  18 October 2005



• Wolf Popper LLP Files Securities Fraud Class Action Against Tag-It Pacific, Inc.
  17 October 2005



• Liberty Corner Capital Sued in Refco Investor Lawsuit Filed by Shalov Stone & Bonner LLP
  16 October 2005



• Blue Coat Announces Dismissal of Securities Class Action Lawsuit
  15 October 2005



• Law Offices Of Charles J. Piven, P.A. Announces Class Action Lawsuit Against Tempur-Pedic International, Inc.
  14 October 2005